A Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis

Trial Profile

A Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2015

At a glance

  • Drugs Abatacept (Primary) ; Azathioprine; Cyclophosphamide; Prednisone
  • Indications Lupus nephritis
  • Focus Therapeutic Use
  • Acronyms ACCESS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Oct 2013 Primary endpoint 'Complete-clinical-response-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top